RVL Pharmaceuticals plc
RVLP
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.8M
Close$
Share Statistics
| Market cap | $2.80 Million |
|---|---|
| Enterprise Value | $42.84 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.58 |
| Beta | 1.09 |
| Outstanding Shares | 99,370,291 |
Return
| Return on Equity | -418.14% |
|---|---|
| Return on Assets | -79.93% |
| Return on Invested Capital | -253.94% |
Valuation & Multiples
| P/E Ratio | -0.05 |
|---|---|
| PEG | -0.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.16 |
| Enterprise Value to EBIT | -0.99 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.38 |
| Debt to Equity | 3.63 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Osmotica Pharmaceuticals Plc
125 employees
CEO: Brian A. Markison RVL Pharmaceuticals plc operates as a specialized drug company, dedicated to innovating and marketing pharmaceutical solutions for patient groups with unmet needs in the ophthalmic and medical aesthetics domains. The firm's activities ex...